Advertisement
Organisation › Details
Xigen S.A.
Xigen, a Swiss biopharmaceutical company founded as a spin-off of the Centre Hospitalier Universitaire Vaudois (CHUV), specializes in the research and development of innovative therapeutic peptides with a focus on inflammatory diseases. The Company’s technology has enabled the design and synthesis of cell-penetrating peptides with enhanced metabolic stability, using proprietary carrier motifs to selectively deliver them to intracellular targets in disease relevant cell types. Xigen’s lead compound Brimapitide (XG-102) is advancing through pre-clinical development with programs in ocular inflammation, urology, nephrology and Alzheimer’s disease. *
Start | 2002-01-14 splitoff | |
Predecessor | CHUV Centre Hospitalier Universitaire Vaudois (University Hospital Lausanne) | |
Industry | anti-inflammatory drug | |
Industry 2 | brimapitide (XG-102) | |
Person | Bonny, Christophe (Enterome 201609– CSO before Bicycle Therapeutics + Xigen + Univ Hospital Lausanne) | |
Region | Epalinges VD | |
Country | Switzerland | |
Street | 4 Route de la Corniche | |
City | 1066 Epalinges VD | |
Tel | +41-21-321-1080 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Xigen S.A.. (1/5/17). "Press Release: Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease". Geneva. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Xigen S.A.
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top